KOD
Kodiak Sciences Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Strong buy
+81/100
Last price
91.58
▼ 2.23 (2.38%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
91.58
Prev close
93.81
Day high
95.44
Day low
89.70
Volume
1.48M
Market cap
$5.80B
P/E (TTM)
—
52W range
10.94 – 104.00
Day trading desk
Gap from prior close
-2.38%
Prior close 93.81
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
91.58 – 91.58
Position in range
—
—
ATR (14D)
9.61
10.49% of price
Prior day high
96.64
PDH
Prior day low
87.58
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 1.56M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+1.34%
-0.6%
1M
+161.14%
+160.0%
3M
+127.27%
+122.8%
6M
+120.96%
+102.8%
YTD
+230.26%
+216.0%
1Y
+513.15%
+496.7%
3Y
+5,030.00%
+4,947.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on KOD open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+2.83M
Net buying
Buy transactions
5
2.86M shares
Sell transactions
1
30.00K shares
Net transactions
+6
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
3.24M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 29, 26 | BAKER BROS ADVISORS L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 715.59K | $63.40M | Indirect |
| Sep 28, 26 | BAKER BROS ADVISORS L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 807.84K | $62.14M | Indirect |
| Sep 25, 26 | PERLROTH VICTOR D Chief Executive Officer |
CONVERSION | 1.28M | $5.38M | Direct |
| Jun 4, 26 | BORGESON JOHN A Chief Financial Officer |
CONVERSION | 30.00K | $31.20K | Direct |
| Jun 4, 26 | BORGESON JOHN A Chief Financial Officer |
SELL | 30.00K | $1.02M | Direct |
| Apr 15, 26 | BORGESON JOHN A Chief Financial Officer |
CONVERSION | 28.61K | $29.76K | Direct |
| Apr 2, 26 | BORGESON JOHN A Chief Financial Officer |
CONVERSION | 30.00K | $31.20K | Direct |
| Apr 2, 26 | BORGESON JOHN A Chief Financial Officer |
SELL | 30.00K | $1.20M | Direct |
| Mar 25, 26 | PERLROTH VICTOR D Chief Executive Officer |
CONVERSION | 300.00K | $312.00K | Direct |
| Dec 26, 25 | PERLROTH VICTOR D Chief Executive Officer |
STOCK | 12.50K | $0 | Direct |
| Dec 18, 25 | BAKER BROS ADVISORS L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 2.61M | $60.00M | Indirect |
| Jun 17, 25 | BORGESON JOHN A Chief Financial Officer |
SELL | 723 | $2.64K | Direct |
| Jun 13, 25 | BORGESON JOHN A Chief Financial Officer |
— | 1.88K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAKER BROS ADVISORS L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
BORGESON JOHN A |
Chief Financial Officer | 211.93K | Conversion of Exercise of derivative security |
PERLROTH VICTOR D |
Chief Executive Officer | 3.68M | Conversion of Exercise of derivative security |
Fundamentals
Market cap$5.80B
Enterprise value$5.72B
Revenue (TTM)—
Gross profit—
EBITDA$-230.98M
Net income$-241.99M
EPS (TTM)$-4.19
Free cash flow$-58.39M
Total cash$125.90M
Total debt$52.76M
Book value / share$0.97
Shares outstanding62.85M
Float36.86M
Short % of float26.87%
Dividend yield0.00%
Beta (5Y)2.04
Valuation & profitability ratios
Trailing P/E—
Forward P/E-26.88
PEG ratio—
Price / sales—
Price / book94.80
EV / revenue—
EV / EBITDA-24.76
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-368.37%
Return on assets-60.45%
Debt / equity86.35
Current ratio2.49
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $182.37M | $126.09M | $206.30M | $267.59M | +44.6% |
| Selling, general & admin | $52.02M | $60.75M | $71.02M | $73.79M | -14.4% |
| Total operating expense | $234.39M | $186.85M | $277.32M | $341.38M | +25.4% |
| Operating income | -$234.39M | -$186.85M | -$277.32M | -$341.38M | -25.4% |
| Net interest income | $4.52M | $11.15M | $16.72M | $7.05M | -59.5% |
| Pre-tax income | -$229.97M | -$176.21M | -$260.49M | -$333.82M | -30.5% |
| Net income | -$229.97M | -$176.21M | -$260.49M | -$333.82M | -30.5% |
| Net income to common | -$229.97M | -$176.21M | -$260.49M | -$333.82M | -30.5% |
| Basic EPS | -4.32 | -3.35 | -4.97 | -6.39 | -29.0% |
| Diluted EPS | -4.32 | -3.35 | -4.97 | -6.39 | -29.0% |
| EBIT | -$229.97M | -$176.21M | -$260.48M | -$333.81M | -30.5% |
| EBITDA | -$203.65M | -$149.50M | -$234.53M | -$322.80M | -36.2% |
| Basic shares | 53.21M | 52.58M | 52.41M | 52.25M | +1.2% |
| Diluted shares | 53.21M | 52.58M | 52.41M | 52.25M | +1.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $209.86M | $168.07M | $285.51M | $190.43M | +24.9% |
| Cash & short-term investments | $209.86M | $168.07M | $285.51M | $478.93M | +24.9% |
| Total current assets | $214.82M | $171.94M | $289.31M | $486.00M | +24.9% |
| Property, plant & equipment | $121.86M | $148.73M | $175.02M | $115.75M | -18.1% |
| Total assets | $351.53M | $335.58M | $479.37M | $666.63M | +4.8% |
| Total current liabilities | $45.53M | $25.57M | $41.73M | $52.50M | +78.1% |
| Total debt | $59.18M | $70.34M | $81.63M | $87.73M | -15.9% |
| Total liabilities | $194.15M | $185.29M | $213.59M | $230.46M | +4.8% |
| Retained earnings | -$1.56B | -$1.33B | -$1.15B | -$892.04M | -17.3% |
| Shareholder equity | $157.38M | $150.29M | $265.78M | $436.17M | +4.7% |
| Working capital | $169.28M | $146.36M | $247.58M | $433.51M | +15.7% |
| Net tangible assets | $157.38M | $150.29M | $265.78M | $436.17M | +4.7% |
| Shares issued | 61.76M | 52.73M | 52.51M | 52.33M | +17.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$229.97M | -$176.21M | -$260.49M | -$333.82M | — | -30.5% |
| Depreciation & amortisation | $26.32M | $26.71M | $25.95M | $11.00M | — | -1.4% |
| Stock-based compensation | $58.86M | $60.21M | $88.56M | $106.03M | — | -2.2% |
| Change in working capital | $6.85M | -$28.39M | -$7.36M | $11.96M | — | +124.1% |
| Operating cash flow | -$136.01M | -$117.32M | -$154.18M | -$206.46M | — | -15.9% |
| Capital expenditure | -$506.00K | -$400.00K | -$41.43M | -$47.36M | — | -26.5% |
| Investing cash flow | -$506.00K | -$755.00K | $249.23M | -$336.51M | — | +33.0% |
| Share buybacks | — | — | — | $0 | $0 | — |
| Financing cash flow | $178.30M | $501.00K | $31.00K | $1.90M | — | +35,489.2% |
| Free cash flow | -$136.51M | -$117.72M | -$195.61M | -$253.82M | — | -16.0% |
| End cash position | $216.05M | $174.26M | $291.83M | $196.76M | — | +24.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $56.08M | $48.55M | $45.49M | $50.48M | $42.76M | +15.5% |
| Selling, general & admin | $10.76M | $11.23M | $11.96M | $11.88M | $12.75M | -4.2% |
| Total operating expense | $66.84M | $59.78M | $57.45M | $62.35M | $55.51M | +11.8% |
| Operating income | -$66.84M | -$59.78M | -$57.45M | -$62.35M | -$55.51M | -11.8% |
| Net interest income | $1.25M | $1.64M | $757.00K | $917.00K | $1.24M | -23.5% |
| Pre-tax income | -$65.64M | -$58.16M | -$56.74M | -$61.46M | -$54.31M | -12.9% |
| Net income | -$65.64M | -$58.16M | -$56.74M | -$61.46M | -$54.31M | -12.9% |
| Net income to common | -$65.64M | -$58.16M | -$56.74M | -$61.46M | -$54.31M | -12.9% |
| Basic EPS | -1.05 | -0.94 | -1.04 | -1.16 | -1.03 | -11.7% |
| Diluted EPS | -1.05 | -0.94 | -1.04 | -1.16 | -1.03 | -11.7% |
| EBIT | -$66.84M | -$59.78M | -$53.03M | -$62.35M | -$55.51M | -11.8% |
| EBITDA | -$60.65M | -$53.44M | -$46.52M | -$55.81M | -$48.97M | -13.5% |
| Basic shares | 62.63M | 61.86M | 54.43M | 52.86M | 52.78M | +1.2% |
| Diluted shares | 62.63M | 61.86M | 54.43M | 52.86M | 52.78M | +1.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $125.90M | $169.53M | $209.86M | $72.04M | $104.17M | -25.7% |
| Cash & short-term investments | $125.90M | $169.53M | $209.86M | $72.04M | $104.17M | -25.7% |
| Total current assets | $131.36M | $175.26M | $214.82M | $75.73M | $107.92M | -25.0% |
| Property, plant & equipment | $110.61M | $115.89M | $121.86M | $127.48M | $133.96M | -4.6% |
| Total assets | $256.81M | $306.01M | $351.53M | $218.07M | $256.73M | -16.1% |
| Total current liabilities | $52.77M | $49.57M | $45.53M | $42.43M | $31.01M | +6.4% |
| Total debt | $52.76M | $55.99M | $59.18M | $62.20M | $65.21M | -5.8% |
| Total liabilities | $195.72M | $193.91M | $194.15M | $194.38M | $186.44M | +0.9% |
| Retained earnings | -$1.68B | -$1.62B | -$1.56B | -$1.50B | -$1.44B | -4.1% |
| Shareholder equity | $61.10M | $112.10M | $157.38M | $23.69M | $70.29M | -45.5% |
| Working capital | $78.59M | $125.69M | $169.28M | $33.30M | $76.91M | -37.5% |
| Net tangible assets | $61.10M | $112.10M | $157.38M | $23.69M | $70.29M | -45.5% |
| Shares issued | 62.83M | 62.16M | 61.76M | 53.00M | 52.82M | +1.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$65.64M | -$58.16M | -$56.74M | -$61.46M | -$54.31M | -12.9% |
| Depreciation & amortisation | $6.19M | $6.34M | $6.51M | $6.54M | $6.54M | -2.4% |
| Stock-based compensation | $11.61M | $12.15M | $13.29M | $14.05M | $15.64M | -4.5% |
| Change in working capital | $1.61M | -$346.00K | -$2.45M | $7.99M | -$2.54M | +565.0% |
| Operating cash flow | -$46.24M | -$40.01M | -$39.38M | -$32.88M | -$34.67M | -15.6% |
| Capital expenditure | -$352.00K | -$942.00K | -$43.00K | -$60.00K | -$133.00K | +62.6% |
| Investing cash flow | -$352.00K | -$942.00K | -$43.00K | -$60.00K | -$133.00K | +62.6% |
| Financing cash flow | $2.96M | $619.00K | $177.25M | $813.00K | $120.00K | +378.7% |
| Free cash flow | -$46.59M | -$40.95M | -$39.42M | -$32.94M | -$34.81M | -13.8% |
| End cash position | $132.09M | $175.71M | $216.05M | $78.22M | $110.35M | -24.8% |
Options analytics
Put / call volume
0.67
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
15.00
-83.8% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
1.72K
Contracts, this expiry
Put volume
1.15K
Contracts, this expiry
Heaviest call OI
15.00
0 contracts
Heaviest put OI
15.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.96 | -1.05 | -9.9% |
| Mar 2026 | -1.01 | -0.94 | +7.1% |
| Dec 2025 | -1.05 | -1.04 | +1.3% |
| Sep 2025 | -1.04 | -1.16 | -11.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.01 | 5 | $0 | 0.0% |
| Next quarter | -0.98 | 5 | $0 | 0.0% |
| Current year | -3.98 | 5 | $0 | 0.0% |
| Next year | -3.44 | 4 | $49.01M | 0.0% |
Analyst targets & ownership
Mean target$116.67
High target$145.00
Low target$96.00
Implied upside27.39%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy1 / 5
Hold1
Sell / Strong sell0 / 0
Held by insiders5.16%
Held by institutions105.55%
Institutions holding272
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
75.20
+21.78% from price
SMA 20
54.11
+70.65% from price
SMA 50
45.71
+102.03% from price
SMA 100
41.42
+121.09% from price
SMA 200
36.31
+154.34% from price
EMA 12
74.97
+22.16% from price
EMA 26
59.44
+54.08% from price
EMA 50
50.50
+81.36% from price
RSI (14)
82.1
Overbought
MACD (12,26,9)
15.53
Hist 5.96
ATR (14)
9.61
10.40% of price
Realised vol 30D
295.9%
Annualised
Bollinger upper
112.09
20, 2σ
Bollinger lower
-3.87
20, 2σ
50 / 200 cross
Golden
45.71 vs 36.31
Trend bias
Above 200
+154.34%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.15
Less volatile than market
Correlation to SPY
0.01
Largely independent
Realised vol 30D
295.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-36.2%
Peak to trough
Max drawdown 5Y
-98.9%
Peak to trough
ATR 14
9.61
10.40% of price
Beta (reported)
2.04
5Y monthly, from filing
Short interest
Shares short
10.67M
Prior 10.30M
Change vs prior
+3.6%
Shorts adding
% of float
26.87%
Heavily shorted
% of shares out
16.98%
Against total outstanding
Days to cover
17.8
Crowded exit
Float
36.86M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 28, 26 | LifeSci Capital | MAINTAINED | Outperform | Outperform |
| Sep 28, 26 | UBS | MAINTAINED | Buy | Buy |
| Sep 28, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 17, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 17, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 3, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| May 11, 26 | Chardan Capital | UPGRADE | Neutral | Buy |
| Mar 27, 26 | UBS | MAINTAINED | Buy | Buy |
| Mar 27, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 22, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 7, 26 | UBS | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-28
Periodic Financial Reports
10-Q · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-06-04
Periodic Financial Reports
10-Q · 2026-05-07
Annual Report to Shareholders
ARS · 2026-04-23
Proxy Statements
DEF 14A · 2026-04-22
Offering Registrations
S-8 · 2026-03-31
Corporate Changes & Voting Matters
8-K · 2026-03-27
Headlines
Kodiak Sciences Stock Pick of the Week at Smart Insider Following Insider Share Purchase
MT Newswires · 21h ago
Kodiak Sciences’ Two Wet AMD Treatments Match Aflibercept in Phase III Study
MarketBeat · 5d ago
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
BioPharma Dive · 5d ago
Kodiak Sciences More Than Doubles on Eye Disease Trial Results
Barchart · 6d ago
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
24/7 Wall St. · 7d ago
This is the top biotech stock pick from B Riley Securities
Investing.com · 8d ago
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
Zacks · 8d ago
What Does Regeneron Pharmaceuticals (REGN) Need To Prove In Eye Disease Now?
Simply Wall St. · 8d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.